Such anti-arrhythmic potential may further support the application of tocilizumab in COVID-19 patients to counteract the risk of adverse QT prolongation and related life-threatening arrhythmias associated with elevated IL-6 and the anti-viral agents. This evidence concerns the gene IL6 and cardiac arrhythmia.